Alto Neuroscience Inc (ANRO)

$6.89 +2.48 (56.24%)
Market Cap 119.41M
Revenue (ttm) 0.00
Net Income (ttm) -61.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.16
Volume 61,880,600
Avg Vol 1,328,038
Day's Range N/A - N/A
Shares Out 27.08M
Stochastic %K 67%
Beta 2.00
Analysts Strong Sell
Price Target $11.00

Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 200 0412
Address:
650 Castro Street, Suite 450, Mountain View, United States
PaulLaurent
PaulLaurent Oct. 4 at 7:33 PM
🌅 4:00am EST Watchlist $CRML – Reuters says U.S. officials discussed an equity stake tied to Tanbreez; prior $50M DPA grant talks may convert to equity (~8% indicative) plus a potential $120M EXIM loan. Capex cited ~$290M; long-term ~85k t/yr concentrate with gallium/tantalum byproducts. Watch terms, funding mix, and policy signals. $SOPA – Ascendiant Capital keeps Buy and lifts PT to 18. Focus on execution of growth initiatives, margin expansion, and near-term updates to validate the bull case. $FEMY – AH runner; no new company-specific headlines in ~36h. Watch for filings, clinical updates, or commercial milestones to explain/extend the move. $NB – Potential multi-day runner. Monitor premarket volume, VWAP reclaims, prior HOD retests. $ANRO – Potential multi-day runner. Look for clean pullbacks to VWAP, liquidity expansion, and momentum continuation. Tone: Policy tailwinds, analyst actions, and AH momentum lead. Favor VWAP/pivot reclaims, trim into strength, keep risk tight.
0 · Reply
GSP
GSP Oct. 4 at 7:28 PM
$LAC $GSM $SES $CCCX $ANRO
0 · Reply
Ccperk
Ccperk Oct. 4 at 2:43 PM
$ANRO only sold 10% yesterday which I’ll buy back in if it goes down. Wondering (hoping) if a short squeeze will happen next week like $DRUG did a year ago. Off exchange short volume ratio is 54% and represents 18 million shares. Seems like these big institutions are shorting. Going to be a battle, we will see
0 · Reply
StockScanners
StockScanners Oct. 4 at 2:36 PM
$ANRO keep watch if this holds above 6.63
0 · Reply
highnihilism
highnihilism Oct. 4 at 2:36 PM
$ANRO Alto Neuroscience volume 57,793,406 | average 179,791 × 321.4 | price 6.89 +2.48 (+56.2%) earnings 08-13-25 amc
0 · Reply
Moneywheel
Moneywheel Oct. 4 at 9:24 AM
$ANRO exited at 8,07$ of all my shares. It has been tough but in the end it was worthwhile to get in and hold them. In at 4,82$. Out of the trade. Congrats again to all who stick to $ANRO when the stock was under 3$….
0 · Reply
Kosztrade
Kosztrade Oct. 4 at 9:21 AM
$ANRO FYI
0 · Reply
highnihilism
highnihilism Oct. 4 at 8:58 AM
$ANRO Alto Neuroscience market cap: 186.5M | 6.89 +56.2% | opening gap +9.1% | % from open +43.2% | volume 57.8M | shares float 21.3M | vol/float 2
0 · Reply
IntraTrades
IntraTrades Oct. 4 at 3:52 AM
$EPSM 73.74% $ANRO 44.75% $FEMY 43.20% $SYTA 38.79%
0 · Reply
Ccperk
Ccperk Oct. 4 at 1:06 AM
$ANRO to all those that plagiarized an S-1 offering earlier, just know that they pulled their S-1 months ago. It seems this company wants to do right by it’s stakeholders. Next week $10 on up.
0 · Reply
Latest News on ANRO
Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 3, 2025, 10:51 AM EDT - 1 day ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Oct 3, 2025, 7:34 AM EDT - 1 day ago

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Sep 13, 2025, 11:50 AM EDT - 21 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

Sep 9, 2025, 7:09 AM EDT - 25 days ago

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 28, 2025, 5:40 PM EDT - 5 weeks ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Aug 27, 2025, 2:17 PM EDT - 5 weeks ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 22, 2025, 10:15 AM EDT - 6 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

Aug 18, 2025, 9:45 AM EDT - 6 weeks ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Aug 18, 2025, 8:45 AM EDT - 6 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Alto Neuroscience to Participate in Upcoming Investor Conferences

Aug 18, 2025, 8:03 AM EDT - 6 weeks ago

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 13, 2025, 4:10 PM EDT - 7 weeks ago

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Aug 13, 2025, 8:03 AM EDT - 7 weeks ago

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

Aug 4, 2025, 2:46 PM EDT - 2 months ago

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jul 22, 2025, 6:25 PM EDT - 2 months ago

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Jun 30, 2025, 8:03 AM EDT - 3 months ago

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Jun 26, 2025, 7:33 AM EDT - 3 months ago

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Jun 3, 2025, 6:03 AM EDT - 4 months ago

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

May 29, 2025, 8:03 AM EDT - 4 months ago

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025, 4:10 PM EDT - 5 months ago

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Apr 28, 2025, 8:03 AM EDT - 5 months ago

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Apr 22, 2025, 8:03 AM EDT - 5 months ago

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

Mar 20, 2025, 4:10 PM EDT - 7 months ago

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Mar 1, 2025, 11:00 AM EST - 7 months ago

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Feb 19, 2025, 8:03 AM EST - 8 months ago

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Feb 12, 2025, 8:03 AM EST - 8 months ago

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud

Feb 2, 2025, 11:00 AM EST - 8 months ago

The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Investigation Into Alto Neuroscience, Inc.

Jan 27, 2025, 11:15 AM EST - 8 months ago

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Investigation Into Alto Neuroscience, Inc.

The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Jan 24, 2025, 1:15 PM EST - 9 months ago

The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Jan 22, 2025, 11:45 AM EST - 9 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

PaulLaurent
PaulLaurent Oct. 4 at 7:33 PM
🌅 4:00am EST Watchlist $CRML – Reuters says U.S. officials discussed an equity stake tied to Tanbreez; prior $50M DPA grant talks may convert to equity (~8% indicative) plus a potential $120M EXIM loan. Capex cited ~$290M; long-term ~85k t/yr concentrate with gallium/tantalum byproducts. Watch terms, funding mix, and policy signals. $SOPA – Ascendiant Capital keeps Buy and lifts PT to 18. Focus on execution of growth initiatives, margin expansion, and near-term updates to validate the bull case. $FEMY – AH runner; no new company-specific headlines in ~36h. Watch for filings, clinical updates, or commercial milestones to explain/extend the move. $NB – Potential multi-day runner. Monitor premarket volume, VWAP reclaims, prior HOD retests. $ANRO – Potential multi-day runner. Look for clean pullbacks to VWAP, liquidity expansion, and momentum continuation. Tone: Policy tailwinds, analyst actions, and AH momentum lead. Favor VWAP/pivot reclaims, trim into strength, keep risk tight.
0 · Reply
GSP
GSP Oct. 4 at 7:28 PM
$LAC $GSM $SES $CCCX $ANRO
0 · Reply
Ccperk
Ccperk Oct. 4 at 2:43 PM
$ANRO only sold 10% yesterday which I’ll buy back in if it goes down. Wondering (hoping) if a short squeeze will happen next week like $DRUG did a year ago. Off exchange short volume ratio is 54% and represents 18 million shares. Seems like these big institutions are shorting. Going to be a battle, we will see
0 · Reply
StockScanners
StockScanners Oct. 4 at 2:36 PM
$ANRO keep watch if this holds above 6.63
0 · Reply
highnihilism
highnihilism Oct. 4 at 2:36 PM
$ANRO Alto Neuroscience volume 57,793,406 | average 179,791 × 321.4 | price 6.89 +2.48 (+56.2%) earnings 08-13-25 amc
0 · Reply
Moneywheel
Moneywheel Oct. 4 at 9:24 AM
$ANRO exited at 8,07$ of all my shares. It has been tough but in the end it was worthwhile to get in and hold them. In at 4,82$. Out of the trade. Congrats again to all who stick to $ANRO when the stock was under 3$….
0 · Reply
Kosztrade
Kosztrade Oct. 4 at 9:21 AM
$ANRO FYI
0 · Reply
highnihilism
highnihilism Oct. 4 at 8:58 AM
$ANRO Alto Neuroscience market cap: 186.5M | 6.89 +56.2% | opening gap +9.1% | % from open +43.2% | volume 57.8M | shares float 21.3M | vol/float 2
0 · Reply
IntraTrades
IntraTrades Oct. 4 at 3:52 AM
$EPSM 73.74% $ANRO 44.75% $FEMY 43.20% $SYTA 38.79%
0 · Reply
Ccperk
Ccperk Oct. 4 at 1:06 AM
$ANRO to all those that plagiarized an S-1 offering earlier, just know that they pulled their S-1 months ago. It seems this company wants to do right by it’s stakeholders. Next week $10 on up.
0 · Reply
BreakoutBullz
BreakoutBullz Oct. 4 at 12:37 AM
🛎️ Trade Recap 🛎️ $DFLI ran 🔥💰🎯 +204% from initial .75 call! $ASNS ran 🔥💰🎯 +52% from .50 call $ANRO ran 🔥💰🎯 +41% from 6.00 call! $BNAI ran 🔥💰🎯 +38% from .50 call! $SYTA ran 🔥💰🎯 +31% from 3.00 call! We posted on ST earlier!📋
0 · Reply
Modsiu
Modsiu Oct. 4 at 12:06 AM
$DFLI $ANRO $BNAI $ASNS $ASTC
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Oct. 4 at 12:01 AM
Comparing trending tickers $RR vs $ANRO: RR is stable at $6.18, but we don't have the volume specifics to make much of it. ANRO, on the other hand, is slightly up at $6.89, again without clear volume details provided. It's tough to say which stock is outperforming without knowing how many shares are moving or the percentage changes, but ANRO is currently priced higher than RR.
2 · Reply
DayTrade_4Life
DayTrade_4Life Oct. 3 at 11:59 PM
3 Oct Results from the Watchlist (WL) and Alerts. -See Profile for more info and to join us. $DFLI: 1.28 to 2.28 (76%); 1.65 breakout (38%) WL & Alert $EPSM $25 to 39.72 (58%) Alert $BNAI: .46 to .69 (50%); .54 breakout (27%) WL & Alert $ANRO: 5.75 to 8.45 (46%) Alert $ASNS: .53 to .76 (46%); .66 breakout (15%) WL ASTC: 5.82 to $8 (37%); 6.35 breakout (25%) WL SYTA: 3.20 to 3.92 (22%) Alert
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Oct. 3 at 11:58 PM
Comparing trending tickers $RR vs $ANRO: RR is currently priced at $6.18, but the percentage change isn't specified, and the volume remains undefined. ANRO is a bit higher at $6.89, also with undefined percentage changes and volume. Without specific volume data, it's tough to gauge the market's enthusiasm, but ANRO is edging out RR in price for now. Both stocks are moving, but exact comparisons are limited without more detailed volume or percentage change data.
0 · Reply
DustinTa
DustinTa Oct. 3 at 11:00 PM
$ANRO holding strong here!
0 · Reply
bSpeed
bSpeed Oct. 3 at 9:57 PM
🚨 $ANRO caught the news early with the squad! Early entries gave us a solid 65% run to end the friday big 🟢🔥💸 Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
0 · Reply
peterpancake
peterpancake Oct. 3 at 9:53 PM
$ANRO $ALTO Neuroscienc And in the pipeline are coming ALTO-100 / ALTO-202 AND ALTO-300, imagine when good news be released about this studies!!!! They have enough cash and an interesting pipeline, good company to skyroket or a target to be purchased by a big pharma
0 · Reply
peterpancake
peterpancake Oct. 3 at 9:53 PM
$ANRO 100,ooo average daily shares to 57 million. Hmmmm. Somebody knows something more than the average retail trader. This is going much higher soon. With early approval this will be $20 in a heartbeat. Buyout at $40.
0 · Reply
JeffersonManvone
JeffersonManvone Oct. 3 at 9:48 PM
$ANRO looking forward to a huge gap up on monday.
1 · Reply
nupasani
nupasani Oct. 3 at 9:35 PM
$ANRO i need this to drop to 5.22
0 · Reply
JeffersonManvone
JeffersonManvone Oct. 3 at 9:26 PM
$ANRO creeping up after hours...
0 · Reply